EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC-ND 4.0

[Translated article] Influence of SARS-CoV-2 infection on the use of ceftazidime-avibactam in the critical patient

Fátima Mayo Olveira, José Manuel Caro Teller, María Dolores Canales Siguero, Sara Ortiz Pérez, María Del Carmen Jiménez León, José Miguel Ferrari Piquero

Farmacia Hospitalaria · 2025

DOI: 10.1016/j.farma.2025.03.016 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Farmacia Hospitalaria, 2025. Verfasst von Fátima Mayo Olveira und 5 weiteren Autor:innen. Beteiligte Einrichtung: Servicio de Farmacia, Hospital Universitario 12 de Octubre, Madrid, España. Electronic address: fatimamayo13@gmail.com. Hauptthemen laut MEDLINE: Ceftazidime, Azabicyclo Compounds, COVID-19, COVID-19 Drug Treatment. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: The objective of the study was to analyse possible changes in antibiotic policy with ceftazidime-avibactam during the SARS-CoV-2 pandemic in an Intensive Care Unit (ICU) to determine patient mortality 28 days after initiation of antimicrobial therapy and to describe the microorganisms that most frequently colonise critically ill patients. MATERIAL AND METHOD: Observational, single-centre, cohort study that included patients on treatment with ceftazidime-avibactam in ICU between March 2020 and September 2021. Demographic (age, sex), microbiological (colonisation, microorganisms isolated in blood cultures), pharmacotherapeutic (duration of treatment with ceftazidime-avibactam, antimicrobials used in synergy with ceftazidime-avibactam) and clinical (mortality, length of hospital stay and comorbidities) variables were collected. As associated comorbidities, we identified how many of the patients included in the study had diabetes mellitus (DM), chronic kidney disease (CKD), chronic obstructive pulmonary disease (COPD) or obesity. RESULTS: Eighty-nine patients were included, 85.39% of whom were male. Forty-nine patients were infected with Sars-CoV-2. Median ICU stay was 46 days (RIQ = 58-27) in SARS-CoV-2 infected and 34 days (RIQ = 51-24) in non-infected patients. Patients were on ceftazidime-avibactam treatment for a median of 8 days (RIQ = 13-4), being 7 days (RIQ = 11-2) in COVID-19 positive patients and 11 days (RIQ = 14-6) in COVID-19 negative patients (p > 0.05). Empirical treatment with ceftazidime-avibactam was started empirically in 41.57% (n = 37) of the patients. The percentage of empiric initiations in SARS-CoV-2 infected patients was 43% and in non-infected patients 40%, with no statistically significant difference between empiric initiation according to SARS-CoV-2 diagnostic status (p > 0.05). A total of 43.8% (n = 39) of the patients were colonised by a multidrug-resistant (MDR) bacterium. Regarding on the microorganisms that colonised patients had, the most frequent was Klebsiella pneumoniae, present in 66.6% of patients (n = 26 patients). Overall mortality was 41.6%, with no statistically significant differences between SARS-CoV-2 infected and non-infected patients (42.9% and 40%, respectively; p > 0.05). CONCLUSION: The SARS-CoV-2 pandemic did not lead to a change in the criteria for the use of ceftazidime-avibactam in the critically ill patient.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CeftazidimeAzabicyclo CompoundsCOVID-19COVID-19 Drug TreatmentAnti-Bacterial AgentsHumansDrug CombinationsMaleFemaleCritical IllnessMiddle AgedAgedIntensive Care UnitsCohort StudiesComorbidityAged, 80 and overLength of StaySARS-CoV-2

Stichwörter der Autor:innen

Ceftazidima-avibactamCeftazidime-avibactamColonisationColonizaciónEmpirical beginningInicio empíricoIntensive Care UnitMedicina intensivaSARS-CoV-2

Substanzen

Ceftazidimeavibactam, ceftazidime drug combinationDrug CombinationsAzabicyclo CompoundsAnti-Bacterial Agents

Autor:innen und Institutionen

  • Servicio de Farmacia, Hospital Universitario 12 de Octubre, Madrid, España. Electronic address: fatimamayo13@gmail.com.
  • Servicio de Farmacia, Hospital Universitario 12 de Octubre, Madrid, España.

Zitieren

APA

Mayo Olveira, F., Caro Teller, J. M., Canales Siguero, M. D., Ortiz Pérez, S., Jiménez León, M. D. C., & Ferrari Piquero, J. M. (2025). [Translated article] Influence of SARS-CoV-2 infection on the use of ceftazidime-avibactam in the critical patient. Farmacia Hospitalaria. https://doi.org/10.1016/j.farma.2025.03.016

Vancouver

Mayo Olveira F, Caro Teller JM, Canales Siguero MD, Ortiz Pérez S, Jiménez León MDC, Ferrari Piquero JM. [Translated article] Influence of SARS-CoV-2 infection on the use of ceftazidime-avibactam in the critical patient. Farmacia Hospitalaria. 2025. doi:10.1016/j.farma.2025.03.016

BibTeX
@article{MayoOlveira2025,
  author = {Mayo Olveira, Fátima and Caro Teller, José Manuel and Canales Siguero, María Dolores and Ortiz Pérez, Sara and Jiménez León, María Del Carmen and Ferrari Piquero, José Miguel},
  title = {[Translated article] Influence of SARS-CoV-2 infection on the use of ceftazidime-avibactam in the critical patient},
  journal = {Farmacia Hospitalaria},
  year = {2025},
  doi = {10.1016/j.farma.2025.03.016}
}
Kostenlos starten →